These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 27405677)

  • 1. State of the art: von Willebrand disease.
    James AH; Eikenboom J; Federici AB
    Haemophilia; 2016 Jul; 22 Suppl 5():54-9. PubMed ID: 27405677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).
    Nichols WL; Hultin MB; James AH; Manco-Johnson MJ; Montgomery RR; Ortel TL; Rick ME; Sadler JE; Weinstein M; Yawn BP
    Haemophilia; 2008 Mar; 14(2):171-232. PubMed ID: 18315614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing treatment of von Willebrand disease by using phenotypic and molecular data.
    Rodeghiero F; Castaman G; Tosetto A
    Hematology Am Soc Hematol Educ Program; 2009; ():113-23. PubMed ID: 20008189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
    Franchini M; Mannucci PM
    Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and management of von Willebrand disease in Spain.
    Batlle J; Perez-Rodriguez A; Pinto JC; Fraga EL; Rodriguez-Trillo Tch A; Fernanda Lopez-Fernandez M
    Semin Thromb Hemost; 2011 Jul; 37(5):503-10. PubMed ID: 22102193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, diagnosis, and management of von Willebrand disease in India.
    Ghosh K; Shetty S
    Semin Thromb Hemost; 2011 Jul; 37(5):595-601. PubMed ID: 22102205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Von Willebrand Disease and Pregnancy: A Review of Evidence and Expert Opinion.
    Reynen E; James P
    Semin Thromb Hemost; 2016 Oct; 42(7):717-723. PubMed ID: 27648611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network.
    Abshire T; Cox-Gill J; Kempton CL; Leebeek FW; Carcao M; Kouides P; Donfield S; Berntorp E
    J Thromb Haemost; 2015 Sep; 13(9):1585-9. PubMed ID: 25930155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of von Willebrand disease in Australia.
    Favaloro EJ; Bonar R; Favaloro J; Koutts J
    Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand Disease: Diagnostic Strategies and Treatment Options.
    Ng CJ; Di Paola J
    Pediatr Clin North Am; 2018 Jun; 65(3):527-541. PubMed ID: 29803281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand disease: Diagnosis and treatment, treatment of women, and genomic approach to diagnosis.
    Laffan M; Sathar J; Johnsen JM
    Haemophilia; 2021 Feb; 27 Suppl 3():66-74. PubMed ID: 32578345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Age on von Willebrand Factor and Bleeding Symptoms in von Willebrand Disease.
    Seaman CD; Ragni MV
    Thromb Haemost; 2020 Aug; 120(8):1159-1165. PubMed ID: 32629500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease.
    Singal M; Kouides PA
    Drugs Today (Barc); 2016 Dec; 52(12):653-664. PubMed ID: 28276537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild forms of von Willebrand disease: diagnosis and management.
    Federici AB
    Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory diagnosis and management of von Willebrand disease in Turkey: Izmir experience.
    Akin M; Kavakli K
    Semin Thromb Hemost; 2011 Jul; 37(5):581-6. PubMed ID: 22102203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.